Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK announces acquisition of Reliant Pharmaceuticals

GSK announces acquisition of Reliant Pharmaceuticals

22nd November 2007

GlaxoSmithKline (GSK) has announced that it is to acquire Reliant Pharmaceuticals for $1.65 billion (800 million pounds) in cash.

The two companies have reached an agreement on the acquisition which is now subject to approval by the US Federal Trade Commission with a decision expected by the end of the year.

The move will expand GSK’s cardiovascular portfolio as the acquisition will see Reliant’s Lovaza added to the GSK product range.

Lovaza is a treatment indicated to reduce triglyceride levels in adults with very high amounts of the fatty substance.

Formerly known as Omacor, Lovaza has seen a rapid uptake among patients and healthcare professions with sales of $206 million for the nine months ending September 30th.

Chris Viehbacher, president of US Pharmaceuticals at GSK, confirmed: “The addition of Lovaza to the GSK portfolio adds a new driver of sales growth in the US business.”

He went on to suggest that the addition of Lovaza would complement GSK’s own treatment for heart failure and hypertension – Coreg CR – and extend it growing profile in the cardiovascular disease area.

Also this week, GSK and Genmab have initiated a Phase III programme investigating the use of ofatumumab in the treatment of rheumatoid arthritis.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.